| Literature DB >> 25294986 |
Cuiping Tian1, Kaiyan Wang2, Wei Ke3, Hui Guo4, Yousheng Shu3.
Abstract
Studies in rodents revealed that selective accumulation of Na(+) channel subtypes at the axon initial segment (AIS) determines action potential (AP) initiation and backpropagation in cortical pyramidal cells (PCs); however, in human cortex, the molecular identity of Na(+) channels distributed at PC axons, including the AIS and the nodes of Ranvier, remains unclear. We performed immunostaining experiments in human cortical tissues removed surgically to cure brain diseases. We found strong immunosignals of Na(+) channels and two channel subtypes, NaV1.2 and NaV1.6, at the AIS of human cortical PCs. Although both channel subtypes were expressed along the entire AIS, the peak immunosignals of NaV1.2 and NaV1.6 were found at proximal and distal AIS regions, respectively. Surprisingly, in addition to the presence of NaV1.6 at the nodes of Ranvier, NaV1.2 was also found in a subpopulation of nodes in the adult human cortex, different from the absence of NaV1.2 in myelinated axons in rodents. NaV1.1 immunosignals were not detected at either the AIS or the nodes of Ranvier of PCs; however, they were expressed at interneuron axons with different distribution patterns. Further experiments revealed that parvalbumin-positive GABAergic axon cartridges selectively innervated distal AIS regions with relatively high immunosignals of NaV1.6 but not the proximal NaV1.2-enriched compartments, suggesting an important role of axo-axonic cells in regulating AP initiation in human PCs. Together, our results show that both NaV1.2 and NaV1.6 (but not NaV1.1) channel subtypes are expressed at the AIS and the nodes of Ranvier in adult human cortical PCs, suggesting that these channel subtypes control neuronal excitability and signal conduction in PC axons.Entities:
Keywords: axon initial segment; chandelier cell; human cortex; node of Ranvier; parvalbumin; pyramidal cell; sodium channel subtype
Year: 2014 PMID: 25294986 PMCID: PMC4172021 DOI: 10.3389/fncel.2014.00297
Source DB: PubMed Journal: Front Cell Neurosci ISSN: 1662-5102 Impact factor: 5.505
Summary of clinical and surgical data.
| No. | Age (yr), sex, side | Duration (yr) | Possible precipitating event | Seizure type | Seizure frequency (times/week) | Status epilepsy | Surgery removal area |
|---|---|---|---|---|---|---|---|
| 1 | 5, F, R | 2 | Unknown | PC, gen | 0.5–0.75 | No | Anterior temporal lobe |
| 2 | 25, M, R | 1 | Pilocytic astrocytoma | PC | 1.5–14 | No | Anterior temporal lobe |
| 3 | 6, M, R | 6 | Cyst | PC, gen | 1 | No | Anterior temporal lobe |
| 4 | 41, F, L | 4 | Unknown | PC, gen | 2–2.5 | No | Anterior temporal lobe |
| 5 | 18, M, R | 9 | Birth problem | PC, gen | 7–14 | No | Anterior temporal lobe |
| 6 | 42, M, L | 18 | High fever | PC, gen | 7–35 | No | Anterior temporal lobe |
| 7 | 52, M, L | 20 | Cyst | PC | 1–2 | No | Anterior temporal lobe |
| 8 | 24, M, R | 11 | Meningioma | PC, gen | 1 | Yes | Anterior temporal lobe |
| 9 | 44, M, R | 4 | Hemangioma | PC, gen | 3–14 | No | Anterior temporal lobe |
| 10 | 23, F, R | 7 | Unknown | PC, gen | 0.5–1 | No | Anterior portion of the medial and inferior frontal gyrus |
| 11 | 22, F, R | 20 | Encephalitis | PC | 14–35 | Yes | Anterior temporal lobe |
| 12 | 57, F, R | 10 | Neurilemmoma in the middle cranial fossa | Anterior temporal lobe | |||
| 13 | 79, M, L | 2 h | 17pcLacunar infarction of bilateral basal ganglia and right thalamus Brain hemorrhage of left thalamus | Junction area of temporal, parietal and occipital lobe | |||
| 14 | 52, M, R | 0.5 | 17pcGlioma in the junction area of parietal and occipital lobe and in the corpus callosum | Junction area of parietal and occipital lobe | |||
| 15 | 45, M, L | 5 | Recurrent tumor in the frontal lobe | Frontal lobe | |||
Summary of tissue samples used for different figures.
| Figure | Patient no. in Table | Sample size ( | Figure | Patient no. in Table | Sample size ( |
|---|---|---|---|---|---|
| Epi: 1,2,4,5,7 | 5 | Epi: 10,11 | 2 | ||
| Ctrl: 12–15 | 4 | Epi: 2,4,5,8,9,11 | 6 | ||
| Epi: 2,4,5 | 3 | Ctrl: 12–15 | 4 | ||
| Ctrl: 12–15 | 4 | Epi: 2,4,5 | 3 | ||
| Epi: 8,9,11 | 3 | Ctrl: 12–15 | 4 | ||
| Epi: 2,4,5,7 | 4 | Epi: 3,5,6,8 | 4 | ||
| Ctrl: 12–15 | 4 | Epi: 6,8 | 2 | ||
| Epi: 2,4,5 | 3 | Epi: 3,5,6 | 3 | ||
| Ctrl: 12–15 | 4 |
Different fixation protocols for immunostaining.
| Double or triple staining | Fixative | Fixation and cutting procedures |
|---|---|---|
| Pan-NaV(R),NeuN(M), AnkG(G) NaV1.2(R), NeuN (M), AnkG(G) NaV1.6(R), NeuN (M), AnkG(G) NaV1.1(R), AnkG(G) | 0.5% | Freezing sectioning of unfixed tissue blocksFixation for 15 min. |
| PV (R), NeuN (M), AnkG(G) NaV1.6(R), MBP (M), AnkG(G) | 4% | Block fixation for 2–4 h and sucrose dehydration |
| GAT-1 (R), PV (M), V-GAT (GP) NaV1.6(R), PV (M), AnkG(G) NaV1.6(R), AnkG(G) | 2% | Freezing sectioning. |
| NaV1.6(R), AnkG(G) | 0.5% | Animal perfusion |
| NaV1.2(R),NaV1.2 (M), AnkG(G) | 0.5% | Freezing sectioning of unfixed tissues; Fixation for 15 min. |